VELINOTAMIG
UNII VT894H6T3S
Substance Identification & Data
This profile provides standardized clinical and technical data for Velinotamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) VT894H6T3S.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2848586-49-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
VT894H6T3S
2848586-49-0
N/A
Detailed Substance Profile
Preferred Name
VELINOTAMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13145
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Velinotamig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Velinotamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Velinotamig
Common Names & Synonyms
H-gamma1 heavy chain anti-CD3E Homo sapiens (1-445) [VH (Homo sapiens IGHV3-33*01 (94.9%) -(IGHD) -IGHJ2*01 (88.2%), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*03 G1m3, nG1m1 CH1 R120, CH3 E12, M14, G1v39 CH2 F1.3, E1.2, S116, G1v74-216), hinge 1-12 P2>R (218), DKTHT 6-10 > VE (222, 223) (217-228), CH2 L1.3>F (232), L1.2>E (233), P116>S (329) (229-338), CH3 S10>C (352), E12 (354), M14 (356), T22>W (364) (339-443), CHS (444-445)) (119-445)], (221-214')-disulfide with common L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (90.5%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; H-gamma1 heavy chain anti-TNFRSF17 Homo sapiens (1''-448'') [VH (Homo sapiens IGHV1-3*01 (81.6%) -(IGHD) -IGHJ4*01 (85.7%) L123>T (116''), CDR-IMGT [8.8.14] (26''-33''.51''-58''.97''-110'')) (1''-121'') -Homo sapiens IGHG1*03 noG1m3, nG1m1 CH1 T120, CH3 E12, M14, G1v39 CH2 F1.3, E1.2, S116, G1v75 CH3 C5, G1v33 CH3 S22, A24, V86 (hole) (CH1 G16>E (141''), N107>D (207''), R120>T (218'') (122''-219''), hinge 1-12 P2>R (221''), DKTHT 6-10 > VE (225'', 226'') (220''-231''), CH2 L1.3>F (235''), L1.2>E (236''), H30>Q (269''), K38>Q (275''), P116>S (332'') (232''-341''), CH3 Y5>C (350''), R11>Q (356''), E12 (357''), M14 (359''), T22>S (367''), L24>A (369''), Y86>V (408''), Q98>E (420'') (342''-446''), CHS (447''-448'')) (122''-448'')], (224''-214''')-disulfide with common L-kappa light chain Homo sapiens (1'''-214''') [V-KAPPA (Homo sapiens IGKV1-39*01 (90.5%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'''-32'''.50'''-52'''.89'''-97''')) (1'''-107''') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'''), V101 (191''')) (108'''-214''')]; dimer (224-227'':227-230'':352-350'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa CH3 C10, G1v32 CH3 W22 (knob) (CH1 R120 (215) (119-216), hinge 1-12 P2>R (218), DKTHT 6-10 > VE (222, 223) (217-228), CH2 L1.3>F (232), L1.2>E (233), P116>S (329) (229-338), CH3 S10>C (352), E12 (354), M14 (356), T22>W (364) (339-443), CHS (444-445)) (119-445)], (221-214')-disulfide with common L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (90.5%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; H-gamma1 heavy chain anti-TNFRSF17 Homo sapiens (1''-448'') [VH (Homo sapiens IGHV1-3*01 (81.6%) -(IGHD) -IGHJ4*01 (85.7%) L123>T (116''), CDR-IMGT [8.8.14] (26''-33''.51''-58''.97''-110'')) (1''-121'') -Homo sapiens IGHG1*03 noG1m3, nG1m1 CH1 T120, CH3 E12, M14, G1v39 CH2 F1.3, E1.2, S116, G1v75 CH3 C5, G1v33 CH3 S22, A24, V86 (hole) (CH1 G16>E (141''), N107>D (207''), R120>T (218'') (122''-219''), hinge 1-12 P2>R (221''), DKTHT 6-10 > VE (225'', 226'') (220''-231''), CH2 L1.3>F (235''), L1.2>E (236''), H30>Q (269''),
Immunoglobulin G1 [141-glutamic acid,207-aspartic acid,218-threonine,235-phenylalanine,236-glutamic acid,269-glutamine,275-glutamine,332-serine,350-cysteine,356-glutamine,367-serine,369-alanine,408-valine,420-glutamic acid], bispecific, anti-(human tumor necrosis factor receptor superfamily protein TNFRSF17) (human-Mus musculus monoclonal GR1803 γ1-chain), disulfide with human-Mus musculus monoclonal GR1803 κ-chain, (227→224′),(230→227′),(350→352′)-tris(disulfide) with immunoglobulin G1 [232′-phenylalanine,233′-glutamic acid,329′-serine, 352′-cysteine,364′-tryptophan] anti-(human CD3 antigen) (human monoclonal GR1803 γ1-chain) disulfide with human monoclonal GR1803 κ-chain
Velinotamig [WHO-DD]
immunoglobulin H-gamma1_L-kappa/H-gamma1_L-kappa, anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)] and anti-[Homo sapiens TNFRSF17 (tumor necrosis factor (TNF) receptor superfamily member 17, B cell maturation antigen, BCMA, TNFRSF13A, CD269)], Homo sapiens monoclonal antibody, bispecific
velinotamig [INN]
